Henry Schein, Inc.
HSIC Healthcare Medical Distribution
Henry Schein, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.2 billion, up 4.03% from fiscal 2024. In the quarter to June 2026, revenue grew 6.73%, EPS grew 16.9%, free cash flow grew 140.9% and total debt rose 15.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow HSIC
Henry Schein, Inc. (HSIC) Net income
Henry Schein, Inc.'s net income for fiscal 2025 was $419.0M, up 5.28% from $398.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $426.0M. Over the past ten years it has ranged from $398.0M (fiscal 2024) to $719.1M (fiscal 2019); the current reading is higher than 18% of that period. Henry Schein, Inc. ranks 4th of 11 Medical Distribution companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $419.0M | 5.28% |
| FY2024 | $398.0M | (8.72%) |
| FY2023 | $436.0M | (22.97%) |
| FY2022 | $566.0M | (14.24%) |
| FY2021 | $660.0M | 57.14% |
| FY2020 | $420.0M | (41.60%) |
| FY2019 | $719.1M | 27.93% |
| FY2018 | $562.1M | 22.39% |
| FY2017 | $459.3M | (17.45%) |
| FY2016 | $556.4M | 6.30% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $102.0M | (8.93%) |
| Mar 2026 | $112.0M | 8.74% |
| Dec 2025 | $103.0M | (5.50%) |
| Sep 2025 | $109.0M | 15.96% |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| MCK McKesson Corporation compare | $5.3B |
| COR Cencora, Inc. compare | $2.6B |
| CAH Cardinal Health, Inc. compare | $1.7B |
| HSIC Henry Schein, Inc. | $426.0M |
| AHG Akso Health Group Sponsored ADR compare | $15.6M |
| HKPD Cellyan Biotechnology Co., Ltd compare | −$180.4K |
| COSM Cosmos Health Inc. compare | −$24.4M |
| FOCL FocalTherics compare | −$39.0M |
| ACH Accendra Health, Inc. compare | −$302.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on HSIC
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement